Lakeshore Biopharma Appoints Advisors to Review Takeover Bid

Lakeshore Biopharma has appointed advisors to a special committee reviewing a takeover bid. The biopharmaceutical company is dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. Its vaccine product, YSJATM rabies vaccine, has been commercialized, and several other products are in various clinical development stages, including PIKA rabies vaccine and PIKA recombinant COVID-19 vaccine.

LakeShore Biopharma Co., Ltd. (Nasdaq: LSB), a global biopharmaceutical company specializing in the discovery, development, and commercialization of new generations of vaccines and therapeutic biologics for infectious diseases and cancer, has appointed advisors to a special committee reviewing a takeover bid. The company announced the appointments on September 10, 2025.

The independent special committee of the company's board of directors has retained Kroll, LLC as its financial advisor, Gibson, Dunn & Crutcher LLP as its U.S. legal counsel, and Maples and Calder (Hong Kong) LLP as its Cayman Islands legal counsel. The committee is continuing its review and evaluation of the previously announced revised preliminary non-binding proposal letter dated August 26, 2025 [^NUMBER].

LakeShore Biopharma's vaccine product, YSJATM rabies vaccine, has been commercialized, and several other products are in various clinical development stages, including PIKA rabies vaccine and PIKA recombinant COVID-19 vaccine. The company operates in China, Singapore, and the Philippines, and is led by a management team with rich local expertise and global experience in the biopharmaceutical industry.

The board cautions shareholders and others considering trading the company's securities that no decisions have been made with respect to the proposal. There is no assurance that any definitive offer will be received, that any definitive agreement will be executed, or that the transaction will be approved or consummated. The company does not undertake any obligation to provide updates regarding the transaction, except as required under applicable law.

LakeShore Biopharma's forward-looking statements involve inherent risks and uncertainties, including the company's strategies, future business development, financial condition, results of operations, ability to maintain relationships with major strategic investors, ability to deliver products and services, ability to maintain and enhance the recognition and reputation of its brands, and general economic and business conditions globally and in China. Further information regarding these risks is included in the company's filings with the U.S. Securities and Exchange Commission (SEC).

For more information, please visit [LakeShore Biopharma's investor relations website](https://investors.lakeshorebio.com/).